Efmoroctocog alfa - Bioverativ/Swedish Orphan Biovitrum

Drug Profile

Efmoroctocog alfa - Bioverativ/Swedish Orphan Biovitrum

Alternative Names: Antihaemophilic factor VIII (recombinant), Fc fusion protein; BIIB-031; Efmoroctocog alfa; Efraloctocog alfa; Elocta; Eloctate; Factor VIII-Fc; FVIII-Fc; Long-lasting factor VIII fusion protein; Recombinant factor VIII Fc; Recombinant factor VIII Fc fusion protein; rFVIII-Fc

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer Bioverativ; Swedish Orphan Biovitrum; Syntonix Pharmaceuticals
  • Class Blood coagulation factors; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 08 Mar 2018 Bioverativ has been acquired by Sanofi
  • 01 Nov 2017 Launched for Haemophilia A in Saudi Arabia (IV) before November 2017
  • 01 Oct 2017 Bioverativ completes the phase III extension ASPIRE trial in Haemophilia A in Australia, Austria, Belgium, Brazil, Canada, France, Germany, Hong Kong, India, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Poland, South Africa, Spain, Switzerland, United Kingdom and USA (NCT01454739)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top